Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 18/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.38 |
| ▸ | PLA2G2E | Q9NZK7 | 4/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.38 |
| ▸ | PLA2G2F | Q9BZM2 | 2/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.38 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.38 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.38 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.38 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7010405 | 0.85 | PLA2G1B (0.47) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7011352 | 0.75 | FOLH1 (0.47) | PLA2G1B | |
| SCHEMBL7014122 | 0.72 | PLA2G1B (0.53) | PLA2G1BPLA2G2A | |
| SCHEMBL8345231 | 0.72 | KDM4E (0.45) | PLA2G1B | |
| SCHEMBL3952696 | 0.70 | RXRA (0.49) | PLA2G1B | |
| SCHEMBL7014263 | 0.68 | PLA2G1B (0.39) | PLA2G1B | |
| SCHEMBL7017189 | 0.68 | PLA2G1B (0.84) | PLA2G1BPLA2G2APLA2G2EPLA2G5 | |
| SCHEMBL7008241 | 0.67 | PLA2G1B (0.68) | PLA2G1BPLA2G2APLA2G2EPLA2G5 | |
| SCHEMBL13794527 | 0.67 | MAPT (0.45) | — | |
| SCHEMBL7011022 | 0.67 | KDM4E (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6645976-B1 | Nonpancreatic secretory phospholipase (sPLA2) supressors such as 2-(3-Benzyl-8-hydroxy-2-ethylindolizin-1-yl)acetamide, administered to control release of fatty acid and prevent the arachidonic acid cascade; septic shock | ELI LILLY AND COMPANY | 2003-11-11 | — | — | US | disclosed |
| EP-0772596-B1 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 2003-10-01 | — | — | EP | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |